Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.45 |
| ▸ | FEN1 | P39748 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111509 | 0.85 | NSD2 (0.50) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL29535297 | 0.82 | NSD2 (0.49) | NSD2PTGES2KDM4EMEN1NPC1 | |
| SCHEMBL29535047 | 0.82 | NSD2 (0.66) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL24429357 | 0.81 | MAPT (0.50) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL791010 | 0.81 | PTGES2 (0.54) | PTGES2LMNAALOX5APFEN1ALDH1A1 | |
| SCHEMBL24429431 | 0.80 | NSD2 (0.46) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL4058096 | 0.79 | ALOX5AP (0.56) | ALOX5APFEN1 | |
| SCHEMBL28712389 | 0.79 | PTGES2 (0.56) | PTGES2ALDH1A1 | |
| SCHEMBL2803354 | 0.78 | NSD2 (0.58) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL5556357 | 0.77 | PTGES2 (0.58) | PTGES2ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | NSD2 3784/4885PTGES2 2154/4885KDM4E 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.